Nespo

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
29-01-2009
Summary of Product characteristics Summary of Product characteristics (SPC)
29-01-2009
Public Assessment Report Public Assessment Report (PAR)
29-01-2009

Active ingredient:

darbepoetin alfa

Available from:

Dompé Biotec S.p.A.

ATC code:

B03XA02

INN (International Name):

darbepoetin alfa

Therapeutic group:

Antianemični preparati

Therapeutic area:

Kidney Failure, Chronic; Anemia; Cancer

Therapeutic indications:

Zdravljenje simptomatske anemije, povezane s kronično odpovedjo ledvic (CRF) pri odraslih in pediatričnih bolnikih. Zdravljenje simptomatsko anemija pri odraslih bolnikov z rakom z non-mieloično malignancies, ki prejemajo kemoterapijo.

Product summary:

Revision: 19

Authorization status:

Umaknjeno

Authorization date:

2001-06-08

Patient Information leaflet

                                Zdravilo nima veā dovoljenja za promet
1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima veā dovoljenja za promet
2
1.
IME ZDRAVILA
Nespo 10 mikrogramov raztopina za injiciranje v napolnjeni injekcijski
brizgi.
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena napolnjena injekcijska brizga vsebuje 10 mikrogramov darbepoetina
alfa v 0,4 ml (25 µg/ml).
Darbepoetin alfa je pridobljen z gensko tehnologijo v ovarijskih
celicah kitajskega hrčka (CHO-K1).
Za pomožne snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravljenje simptomatske anemije, povezane s kronično odpovedjo
ledvic pri odraslih in pri
pediatričnih bolnikih.
Zdravljenje simptomatske anemije pri odraslih onkoloških bolnikih z
nemieloidnimi malignomi, ki
dobivajo kemoterapijo.
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje z Nespom mora uvesti zdravnik, ki ima izkušnje z
navedenima indikacijama.
Nespo je na voljo pripravljen za uporabo v napolnjeni injekcijski
brizgi. Navodila za uporabo,
ravnanje z zdravilom in odlaganje so navedena v poglavju 6.6.
_ZDRAVLJENJE SIMPTOMATSKE ANEMIJE PRI ODRASLIH IN PEDIATRIČNIH
BOLNIKIH S KRONIČNO ODPOVEDJO LEDVIC _
Simptomi in posledice anemije se lahko razlikujejo glede na starost,
spol in celotno breme bolezni;
zdravnik mora oceniti klinični potek in stanje pri posameznem
bolniku. Nespo je treba aplicirati
subkutano ali intravensko. Cilj je zvišanje hemoglobina na ne več
kot 120 g/l (7,5 mmol/l). Pri
bolnikih, ki niso na hemodializi, ima prednost subkutana uporaba, ker
tako ni potrebno zbadanje
perifernih ven.
Zaradi variabilnosti med bolniki se lahko tu in tam pri posameznem
bolniku pojavijo vrednosti
hemoglobina, ki so višje ali nižje od želene koncentracije.
Variabilnosti hemoglobina se je treba
prilagoditi z uravnavanjem odmerka, pri čemer je treba upoštevati
ciljno območje koncentracije
hemoglobina od 100 g/l (6,2 mmol/l) do 120 g/l (7,5 mmol/l). Izogniti
se je treba temu,
                                
                                Read the complete document

Summary of Product characteristics

                                Zdravilo nima veā dovoljenja za promet
1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima veā dovoljenja za promet
2
1.
IME ZDRAVILA
Nespo 10 mikrogramov raztopina za injiciranje v napolnjeni injekcijski
brizgi.
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena napolnjena injekcijska brizga vsebuje 10 mikrogramov darbepoetina
alfa v 0,4 ml (25 µg/ml).
Darbepoetin alfa je pridobljen z gensko tehnologijo v ovarijskih
celicah kitajskega hrčka (CHO-K1).
Za pomožne snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravljenje simptomatske anemije, povezane s kronično odpovedjo
ledvic pri odraslih in pri
pediatričnih bolnikih.
Zdravljenje simptomatske anemije pri odraslih onkoloških bolnikih z
nemieloidnimi malignomi, ki
dobivajo kemoterapijo.
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje z Nespom mora uvesti zdravnik, ki ima izkušnje z
navedenima indikacijama.
Nespo je na voljo pripravljen za uporabo v napolnjeni injekcijski
brizgi. Navodila za uporabo,
ravnanje z zdravilom in odlaganje so navedena v poglavju 6.6.
_ZDRAVLJENJE SIMPTOMATSKE ANEMIJE PRI ODRASLIH IN PEDIATRIČNIH
BOLNIKIH S KRONIČNO ODPOVEDJO LEDVIC _
Simptomi in posledice anemije se lahko razlikujejo glede na starost,
spol in celotno breme bolezni;
zdravnik mora oceniti klinični potek in stanje pri posameznem
bolniku. Nespo je treba aplicirati
subkutano ali intravensko. Cilj je zvišanje hemoglobina na ne več
kot 120 g/l (7,5 mmol/l). Pri
bolnikih, ki niso na hemodializi, ima prednost subkutana uporaba, ker
tako ni potrebno zbadanje
perifernih ven.
Zaradi variabilnosti med bolniki se lahko tu in tam pri posameznem
bolniku pojavijo vrednosti
hemoglobina, ki so višje ali nižje od želene koncentracije.
Variabilnosti hemoglobina se je treba
prilagoditi z uravnavanjem odmerka, pri čemer je treba upoštevati
ciljno območje koncentracije
hemoglobina od 100 g/l (6,2 mmol/l) do 120 g/l (7,5 mmol/l). Izogniti
se je treba temu,
                                
                                Read the complete document

Similar products

Active ingredient darbepoetin alfa

darbepoetin alfa

ATC code B03XA02

B03XA02

Marketed by Dompé Biotec S.p.A.

Dompé Biotec S.p.A.

INN (International Name) darbepoetin alfa

darbepoetin alfa

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 29-01-2009
Summary of Product characteristics Summary of Product characteristics Bulgarian 29-01-2009
Public Assessment Report Public Assessment Report Bulgarian 29-01-2009
Patient Information leaflet Patient Information leaflet Spanish 29-01-2009
Summary of Product characteristics Summary of Product characteristics Spanish 29-01-2009
Public Assessment Report Public Assessment Report Spanish 29-01-2009
Patient Information leaflet Patient Information leaflet Czech 29-01-2009
Summary of Product characteristics Summary of Product characteristics Czech 29-01-2009
Public Assessment Report Public Assessment Report Czech 29-01-2009
Patient Information leaflet Patient Information leaflet Danish 29-01-2009
Summary of Product characteristics Summary of Product characteristics Danish 29-01-2009
Public Assessment Report Public Assessment Report Danish 29-01-2009
Patient Information leaflet Patient Information leaflet German 29-01-2009
Summary of Product characteristics Summary of Product characteristics German 29-01-2009
Public Assessment Report Public Assessment Report German 29-01-2009
Patient Information leaflet Patient Information leaflet Estonian 29-01-2009
Summary of Product characteristics Summary of Product characteristics Estonian 29-01-2009
Public Assessment Report Public Assessment Report Estonian 29-01-2009
Patient Information leaflet Patient Information leaflet Greek 29-01-2009
Summary of Product characteristics Summary of Product characteristics Greek 29-01-2009
Public Assessment Report Public Assessment Report Greek 29-01-2009
Patient Information leaflet Patient Information leaflet English 29-01-2009
Summary of Product characteristics Summary of Product characteristics English 29-01-2009
Public Assessment Report Public Assessment Report English 29-01-2009
Patient Information leaflet Patient Information leaflet French 29-01-2009
Summary of Product characteristics Summary of Product characteristics French 29-01-2009
Public Assessment Report Public Assessment Report French 29-01-2009
Patient Information leaflet Patient Information leaflet Italian 29-01-2009
Summary of Product characteristics Summary of Product characteristics Italian 29-01-2009
Public Assessment Report Public Assessment Report Italian 29-01-2009
Patient Information leaflet Patient Information leaflet Latvian 29-01-2009
Summary of Product characteristics Summary of Product characteristics Latvian 29-01-2009
Public Assessment Report Public Assessment Report Latvian 29-01-2009
Patient Information leaflet Patient Information leaflet Lithuanian 29-01-2009
Summary of Product characteristics Summary of Product characteristics Lithuanian 29-01-2009
Public Assessment Report Public Assessment Report Lithuanian 29-01-2009
Patient Information leaflet Patient Information leaflet Hungarian 29-01-2009
Summary of Product characteristics Summary of Product characteristics Hungarian 29-01-2009
Public Assessment Report Public Assessment Report Hungarian 29-01-2009
Patient Information leaflet Patient Information leaflet Maltese 29-01-2009
Summary of Product characteristics Summary of Product characteristics Maltese 29-01-2009
Public Assessment Report Public Assessment Report Maltese 29-01-2009
Patient Information leaflet Patient Information leaflet Dutch 29-01-2009
Summary of Product characteristics Summary of Product characteristics Dutch 29-01-2009
Public Assessment Report Public Assessment Report Dutch 29-01-2009
Patient Information leaflet Patient Information leaflet Polish 29-01-2009
Summary of Product characteristics Summary of Product characteristics Polish 29-01-2009
Public Assessment Report Public Assessment Report Polish 29-01-2009
Patient Information leaflet Patient Information leaflet Portuguese 29-01-2009
Summary of Product characteristics Summary of Product characteristics Portuguese 29-01-2009
Public Assessment Report Public Assessment Report Portuguese 29-01-2009
Patient Information leaflet Patient Information leaflet Romanian 29-01-2009
Summary of Product characteristics Summary of Product characteristics Romanian 29-01-2009
Public Assessment Report Public Assessment Report Romanian 29-01-2009
Patient Information leaflet Patient Information leaflet Slovak 29-01-2009
Summary of Product characteristics Summary of Product characteristics Slovak 29-01-2009
Public Assessment Report Public Assessment Report Slovak 29-01-2009
Patient Information leaflet Patient Information leaflet Finnish 29-01-2009
Summary of Product characteristics Summary of Product characteristics Finnish 29-01-2009
Public Assessment Report Public Assessment Report Finnish 29-01-2009
Patient Information leaflet Patient Information leaflet Swedish 29-01-2009
Summary of Product characteristics Summary of Product characteristics Swedish 29-01-2009
Public Assessment Report Public Assessment Report Swedish 29-01-2009

Search alerts related to this product

Alerts Nespo darbepoetin alfa

Nespo darbepoetin alfa

View documents history

Documents history Documents history

Nespo